Zai Lab Limited (HKG: 9688)
Hong Kong
· Delayed Price · Currency is HKD
20.90
+0.40 (1.95%)
Jan 28, 2025, 12:08 PM HKT
Zai Lab Revenue
Zai Lab had revenue of $102.27M USD in the quarter ending September 30, 2024, with 47.72% growth. This brings the company's revenue in the last twelve months to $355.75M, up 35.01% year-over-year. In the year 2023, Zai Lab had annual revenue of $266.72M with 24.03% growth.
Revenue (ttm)
$355.75M
Revenue Growth
+35.01%
P/S Ratio
n/a
Revenue / Employee
$163.56K
Employees
2,175
Market Cap
23.63B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
Dec 31, 2019 | 12.99M | 12.86M | 9,965.89% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 26.04B |
Hansoh Pharmaceutical Group Company | 13.00B |
JD Health International | 58.84B |
WuXi Biologics | 18.39B |
Sinopharm Group | 634.32B |
Alibaba Health Information Technology | 31.39B |
Akeso | 2.01B |
Innovent Biologics | 8.01B |
Zai Lab News
- 2 days ago - Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025 - Business Wire
- 7 days ago - Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC) - Business Wire
- 13 days ago - Chinese regulators accept Zai Lab application for KarXT - Seeking Alpha
- 13 days ago - Zai Lab Ltd (ZLAB) Announces NDA Acceptance for KarXT in China - GuruFocus
- 13 days ago - Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia - Business Wire
- 15 days ago - Zai Lab to seek China approval for cervical cancer therapy after positive trial data - Seeking Alpha
- 15 days ago - Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer - Business Wire
- 20 days ago - Zai Lab Ltd (ZLAB) Partners with Vertex Pharmaceuticals for Povetacicept Development in Asia - GuruFocus